Waters and Lambda Cooperate in Clinical Research

September 17, 2007

Waters Corporation (Milford, Massachusetts) and Lambda Therapeutic Research Ltd (Mumbai, India) recently announced a joint cooperative agreement that provides innovative analytical laboratory equipment designed to enhance research quality service and business solutions for Lambda and its clients.

Waters Corporation

(Milford, Massachusetts) and

Lambda Therapeutic Research Ltd.

(Mumbai, India) recently announced a joint cooperative agreement that provides innovative analytical laboratory equipment designed to enhance research quality service and business solutions for Lambda and its clients.

The agreement enables Lambda to meet its international business goals by fulfilling its needs for innovative laboratory equipment, including mass spectrometry (MS), liquid chromatography (LC), and laboratory software solutions. Additionally, Waters will share its keen understanding of scientific and laboratory management through dedicated training opportunities.

"This agreement positions Lambda and our clients for international success on scientific and business levels," said AK Dasgupta, Director for Lambda Therapeutic Research. "Lambda's mission is to enhance research quality by continuously upgrading techniques and procedures that ensure scientific validity of all research projects. Key to this vision is aligning ourselves with partners who understand our business and provide real solutions on our service and our business. Waters' product lines and strategic vision for laboratory-driven companies makes them a perfect partner for Lambda."

The agreement allows Lambda to adopt several Waters products including the Quattro Premier XE tandem quadrupole mass spectrometer paired with the ACQUITY UPLC system and MassLynx software to address Lambda's need to analyze complex biological samples. This system delivers a complete sensitive platform that is regulatory compliant-ready for clinical laboratories that require superior quantitative results and operational efficiency.

"We recognize Lambda Therapeutic Research achievements as an internationally world-class expert in clinical research," said Art Caputo, President of the Waters Division. "Through this Agreement, Waters seeks to share our global understanding of laboratory analytics and provide innovative products with Lambda to produce meaningful scientific and business impact. We expect this Agreement will reinforce and enhance Lambda's research leadership both in India and worldwide."

In addition to covering technology acquisition plans, Lambda and Waters identified specific knowledge-sharing opportunities as well. Waters will host Lambda scientists at its training center in Manchester, England, and invite internationally-renowned analytical scientists to India for on-site Lambda scientific training. Lastly, Waters India will conduct MS, LC, and sample preparation training at Lambda facilities.